Abstract 554P
Background
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful diagnostic modality for thoracic lymphadenopathies, including primary lung cancer. However, the specimens obtained are often small and inadequate for pathological diagnosis. We previously reported that using the EchoTip ProCore Endobronchial HD ultrasound needle (EchoTip) increased the tissue diagnosis rate in lung cancer (Miyazaki et al., 2021). In previous studies, the Oncomine Dx Target Test (ODxTT) was performed in only one case, and it is unclear whether the specimens collected could tolerate next-generation sequencing (NGS)-based testing.
Methods
We performed a single-center, retrospective observational study. This study included patients who underwent ODxTT between April 1, 2019 and April 30, 2023. Patients were selected and divided into two groups comprising those who underwent EBUS-TBNA and those whose specimens were obtained by other methods. The ODxTT success rate was calculated for each group. This study was approved by the institutional review board in June 2022. (No. 22-06-05).
Results
We enrolled 144 patients:20 in the EBUS-TBNA group and 124 in the other-methods group. In the EBUS-TBNA group, the pathological diagnoses were adenocarcinoma (Ad), squamous cell carcinoma (Sq), and others in 15, 2, and 3 patients, respectively. In contrast, in the other-methods group, the collection methods were endobronchial biopsy and transbronchial biopsy, surgical procedures, computed tomography-guided needle biopsy, and others for 79, 31, 6, and 8 patients, respectively, and the pathological diagnoses were Ad, Sq, and others in 78, 15, and 31 patients, respectively. The success rates of ODxTT for EBUS-TBNA and others were 90% and 86%, respectively. The DNA and RNA inspection success rates of EBUS-TBNA were 95% and 90%, respectively, and those of the other methods were 90% and 94%, respectively.
Conclusions
The success rate of ODxTT on EBUS-TBNA specimens were 90%. It is expected to yield specimens of sufficient quality and quantity to perform ODxTT and may be an important diagnostic option in lung cancer cases with enlarged lymph nodes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Miyazaki: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck KGaA, Eli Lilly Japan K.K., Cook Medical Japan; Financial Interests, Institutional, Research Grant: AbbVie GK, MSD, AstraZeneca, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD. K. Ito, A. Hayashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. A. Shiba: Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Taiho Pharmaceutical CO., LTD., Bristol Myers Squibb, AbbVie GK. Y. Higashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. M. Aga: Financial Interests, Personal, Invited Speaker: TEIJIN PHARMA, Nippon Boehringer Ingelheim Co., Ltd.; Financial Interests, Institutional, Research Grant: AbbVie GK, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca. Y. Hamakawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., AstraZeneca, AbbVie GK. Y. Taniguchi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD. Y. Misumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Nippon Kayaku CO., LTD., Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD. Y. Agemi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd.; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD., MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: AstraZeneca, Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AbbVie GK. T. Shimokawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK. H. Okamoto: Financial Interests, Institutional, Research Grant: MSD, Taiho, Bristol Myers Squibb.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract